Use of NK-1 receptor antagonists for treating bipolar disorders
US5952315A · kind A · utility
20Cited by
7References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 1, 1997 |
| Grant date | Sep 14, 1999 |
| Priority date | — |
| Expiry date | Dec 1, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for the treatment or prevention of bipolar disorder without concomitant therapy with other antidepressant or anti-anxiety agents which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.